IP Library Granted Patent US 8,614,236
Granted Patent B2
US 8,614,236 · App. 11/953,249 · Granted Dec 24, 2013

Methods of treating pulmonary disease using acetazolamide and structurally related derivatives

Inventor: Erik R. Swenson (Mercer Island, WA)
Assignee: University of Washington
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,614,236
App. No.
11/953,249
Granted
Dec 24, 2013
Kind
B2
Abstract

The present invention is directed to a method of treating a subject for a pulmonary disease by administering a therapeutically effective amount of a compound of the formula: wherein R 1 , R 2 or R 3 are each independently a C 1 to C 6 alkyl, a halogen, a sulfate, or a phosphate. The pulmonary disease in the subject can be hypoxic pulmonary vasoconstriction, pulmonary edema, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial fibrosis, high altitude residence, sleep apnea syndrome, atrial septal defects, and pulmonary diseases associated with other conditions. If this same compound is modified so that R 1 , R 2 or R 3 each independently is a C 1 to C 6 alkyl and the compound is not a carbonic acid inhibitor, it can be administered to a subject to block hypoxic pulmonary vasoconstriction and/or prevent high altitude pulmonary edema. Additional aspects of the present invention include an inhalable composition comprising the compound of the above formula without modification and an inhalable carrier, as well as the above modified compound.

Claims (6)

1. A method of treating a subject for a pulmonary disease selected from the group consisting of hypoxic pulmonary vasoconstriction, pulmonary edema, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial fibrosis, high altitude residence, sleep apnea syndrome, and atrial septal defects, said method comprising:

administering to the subject a compound of the formula:

where R 1 and R 3 are each methyl and R 2 is hydrogen;

wherein the compound is administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by inhalation, and/or by application to mucous membranes of the nose, throat, and/or bronchial tubes;

under conditions effective to treat the pulmonary disease in the subject.

2. The method of claim 1 , wherein the subject is human.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 23, 2014
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034699/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2009
From: SWENSON, ERIK R.
To: WASHINGTON, UNIVERSITY OF
Reel/Frame 022133/0926 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded May 22, 2008
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020981/0961 →
Continuity (2)
Provisional Application 60869635 · Dec 12, 2006
Related Publication 20090131490A1 · May 21, 2009